Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
patritumab
- Development stage
- Phase 3
- Lead developer
- Daiichi Sankyo
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Patritumab is a fully human monoclonal antibody that targets the human epidermal growth factor receptor 3 (HER3, also known as ErbB3). By binding to HER3, patritumab inhibits its activation and downstream signaling pathways involved in cell proliferation and survival. HER3 is implicated in the development and progression of various cancers, particularly those with resistance to EGFR tyrosine kinase inhibitors. Patritumab has been investigated primarily for the treatment of non-small cell lung cancer (NSCLC), solid tumors, head and neck neoplasms, among others[3]. It serves as the antibody component in the antibody-drug conjugate patritumab deruxtecan.
- Other names
- patritumab deruxtecanU3-1402U-3-1402U 3-1402HER3-DXdHER-3-DXdHER 3-DXd
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on patritumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on patritumab.